Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Peptide-MHC multimer-based monitoring of CD8 T-cells in HIV-1 infection and AIDS vaccine development.

Reguzova AY, Karpenko LI, Mechetina LV, Belyakov IM.

Expert Rev Vaccines. 2015 Jan;14(1):69-84. doi: 10.1586/14760584.2015.962520. Epub 2014 Nov 5. Review.

PMID:
25373312
2.

Novel approaches in polyepitope T-cell vaccine development against HIV-1.

Karpenko LI, Bazhan SI, Antonets DV, Belyakov IM.

Expert Rev Vaccines. 2014 Jan;13(1):155-73. doi: 10.1586/14760584.2014.861748. Epub 2013 Dec 2. Review.

PMID:
24308576
3.

Consensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4+ and CD8+ T cells.

Krotova O, Starodubova E, Petkov S, Kostic L, Agapkina J, Hallengärd D, Viklund A, Latyshev O, Gelius E, Dillenbeck T, Karpov V, Gottikh M, Belyakov IM, Lukashov V, Isaguliants MG.

PLoS One. 2013 May 8;8(5):e62720. doi: 10.1371/journal.pone.0062720. Print 2013.

4.

Improved SIV DNA vaccine can be effectively used as a boost for Ad5 in prime-boost immunization strategy.

Belyakov IM.

Expert Rev Vaccines. 2012 Jul;11(7):787-90. doi: 10.1586/erv.12.46.

PMID:
22913256
5.

Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection.

Zhu Q, Talton J, Zhang G, Cunningham T, Wang Z, Waters RC, Kirk J, Eppler B, Klinman DM, Sui Y, Gagnon S, Belyakov IM, Mumper RJ, Berzofsky JA.

Nat Med. 2012 Aug;18(8):1291-6. doi: 10.1038/nm.2866. Epub 2012 Jul 15.

6.

Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking.

Makidon PE, Belyakov IM, Blanco LP, Janczak KW, Landers J, Bielinska AU, Groom JV 2nd, Baker JR Jr.

Eur J Immunol. 2012 Aug;42(8):2073-86. doi: 10.1002/eji.201142346. Epub 2012 Jul 4.

7.

TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4⁺ memory T cell loss in SIVmac251-challenged rhesus macaques.

Sui Y, Gagnon S, Dzutsev A, Zhu Q, Yu H, Hogg A, Wang Y, Xia Z, Belyakov IM, Venzon D, Klinman D, Strober W, Kelsall B, Franchini G, Berzofsky JA.

Vaccine. 2011 Dec 9;30(1):59-68. doi: 10.1016/j.vaccine.2011.10.043. Epub 2011 Oct 29.

8.

Lack of IL-7 and IL-15 signaling affects interferon-γ production by, more than survival of, small intestinal intraepithelial memory CD8+ T cells.

Isakov D, Dzutsev A, Berzofsky JA, Belyakov IM.

Eur J Immunol. 2011 Dec;41(12):3513-28. doi: 10.1002/eji.201141453.

10.

Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development.

Belyakov IM, Ahlers JD.

Curr Top Microbiol Immunol. 2012;354:157-79. doi: 10.1007/82_2010_119. Review.

PMID:
21203884
11.

Multiple antigen peptide vaccines against Plasmodium falciparum malaria.

Mahajan B, Berzofsky JA, Boykins RA, Majam V, Zheng H, Chattopadhyay R, de la Vega P, Moch JK, Haynes JD, Belyakov IM, Nakhasi HL, Kumar S.

Infect Immun. 2010 Nov;78(11):4613-24. doi: 10.1128/IAI.00533-10. Epub 2010 Sep 7.

12.

Molecular pathways regulating CD4(+) T cell differentiation, anergy and memory with implications for vaccines.

Ahlers JD, Belyakov IM.

Trends Mol Med. 2010 Oct;16(10):478-91. doi: 10.1016/j.molmed.2010.07.007. Epub 2010 Aug 24. Review.

PMID:
20739220
13.

New paradigms for generating effective CD8+ T cell responses against HIV-1/AIDS.

Ahlers JD, Belyakov IM.

Discov Med. 2010 Jun;9(49):528-37.

14.

Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques.

Sui Y, Zhu Q, Gagnon S, Dzutsev A, Terabe M, Vaccari M, Venzon D, Klinman D, Strober W, Kelsall B, Franchini G, Belyakov IM, Berzofsky JA.

Proc Natl Acad Sci U S A. 2010 May 25;107(21):9843-8. doi: 10.1073/pnas.0911932107. Epub 2010 May 10.

15.

Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice.

Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, Klinman DM, Berzofsky JA.

J Clin Invest. 2010 Feb;120(2):607-16. doi: 10.1172/JCI39293. Epub 2010 Jan 25.

16.

Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS.

Ahlers JD, Belyakov IM.

Trends Immunol. 2010 Mar;31(3):120-30. doi: 10.1016/j.it.2009.12.003. Epub 2010 Jan 19. Review.

PMID:
20089450
17.

What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?

Belyakov IM, Ahlers JD.

J Immunol. 2009 Dec 1;183(11):6883-92. doi: 10.4049/jimmunol.0901466. Review.

18.

Memories that last forever: strategies for optimizing vaccine T-cell memory.

Ahlers JD, Belyakov IM.

Blood. 2010 Mar 4;115(9):1678-89. doi: 10.1182/blood-2009-06-227546. Epub 2009 Nov 10. Review.

19.

Strategies for optimizing targeting and delivery of mucosal HIV vaccines.

Ahlers JD, Belyakov IM.

Eur J Immunol. 2009 Oct;39(10):2657-69. doi: 10.1002/eji.200939269. Review.

20.

Non-equilibrium and differential function between intraepithelial and lamina propria virus-specific TCRalphabeta(+) CD8alphabeta(+) T cells in the small intestinal mucosa.

Isakov D, Dzutsev A, Belyakov IM, Berzofsky JA.

Mucosal Immunol. 2009 Sep;2(5):450-61. doi: 10.1038/mi.2009.95. Epub 2009 Jul 1.

21.

Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines.

Ahlers JD, Belyakov IM.

Trends Mol Med. 2009 Jun;15(6):263-74. doi: 10.1016/j.molmed.2009.04.003. Epub 2009 May 30. Review.

PMID:
19487159
22.

Comment on "trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination".

Belyakov IM, Ahlers JD.

J Immunol. 2009 Feb 15;182(4):1779; author reply 1779-80. doi: 10.4049/jimmunol.0990002. No abstract available.

23.

Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines.

Zhu Q, Egelston C, Vivekanandhan A, Uematsu S, Akira S, Klinman DM, Belyakov IM, Berzofsky JA.

Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16260-5. doi: 10.1073/pnas.0805325105. Epub 2008 Oct 9.

24.

Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.

Belyakov IM, Ahlers JD.

Trends Immunol. 2008 Nov;29(11):574-85. doi: 10.1016/j.it.2008.07.010. Review.

PMID:
18838298
25.

The IL-15 receptor {alpha} chain cytoplasmic domain is critical for normal IL-15Ralpha function but is not required for trans-presentation.

Wu Z, Xue HH, Bernard J, Zeng R, Issakov D, Bollenbacher-Reilley J, Belyakov IM, Oh S, Berzofsky JA, Leonard WJ.

Blood. 2008 Dec 1;112(12):4411-9. doi: 10.1182/blood-2007-03-080697. Epub 2008 Sep 16.

26.

Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.

Belyakov IM, Ahlers JD, Nabel GJ, Moss B, Berzofsky JA.

Virology. 2008 Nov 10;381(1):106-15. doi: 10.1016/j.virol.2008.08.019. Epub 2008 Sep 14.

27.

Estimation of low frequency antigen-presenting cells with a novel RELISPOT assay.

Dzutsev AK, Belyakov IM, Isakov DV, Gagnon SJ, Margulies DH, Berzofsky JA.

J Immunol Methods. 2008 Apr 20;333(1-2):71-8. doi: 10.1016/j.jim.2008.01.008. Epub 2008 Feb 8.

28.
29.

Role of alpha3 domain of class I MHC molecules in the activation of high- and low-avidity CD8+ CTLs.

Belyakov IM, Kozlowski S, Mage M, Ahlers JD, Boyd LF, Margulies DH, Berzofsky JA.

Int Immunol. 2007 Dec;19(12):1413-20. Epub 2007 Nov 1.

PMID:
17981793
31.

Avidity of CD8 T cells sharpens immunodominance.

Dzutsev AH, Belyakov IM, Isakov DV, Margulies DH, Berzofsky JA.

Int Immunol. 2007 Apr;19(4):497-507. Epub 2007 Mar 21.

PMID:
17376783
33.

The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response.

Kotelkin A, Belyakov IM, Yang L, Berzofsky JA, Collins PL, Bukreyev A.

J Virol. 2006 Jun;80(12):5958-67. Erratum in: J Virol. 2006 Oct;80(20):10286.

34.

Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.

Pal R, Venzon D, Santra S, Kalyanaraman VS, Montefiori DC, Hocker L, Hudacik L, Rose N, Nacsa J, Edghill-Smith Y, Moniuszko M, Hel Z, Belyakov IM, Berzofsky JA, Parks RW, Markham PD, Letvin NL, Tartaglia J, Franchini G.

J Virol. 2006 Apr;80(8):3732-42.

35.

Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.

Belyakov IM, Kuznetsov VA, Kelsall B, Klinman D, Moniuszko M, Lemon M, Markham PD, Pal R, Clements JD, Lewis MG, Strober W, Franchini G, Berzofsky JA.

Blood. 2006 Apr 15;107(8):3258-64. Epub 2005 Dec 22.

37.

Fixation and cryopreservation of whole blood and isolated mononuclear cells: Influence of different procedures on lymphocyte subset analysis by flow cytometry.

Pinto LA, Trivett MT, Wallace D, Higgins J, Baseler M, Terabe M, Belyakov IM, Berzofsky JA, Hildesheim A.

Cytometry B Clin Cytom. 2005 Jan;63(1):47-55.

39.

Progress on new vaccine strategies against chronic viral infections.

Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, Terabe M, Belyakov IM.

J Clin Invest. 2004 Aug;114(4):450-62. Review.

40.

Mucosal AIDS vaccines: current status and future directions.

Belyakov IM, Ahlers JD, Berzofsky JA.

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S65-73. Review.

PMID:
15285706
41.
42.

Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC.

J Clin Invest. 2004 Jun;113(11):1515-25. Review.

43.

Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA.

J Clin Invest. 2004 Apr;113(7):998-1007.

44.

Molecular mechanisms and biological significance of CTL avidity.

Snyder JT, Alexander-Miller MA, Berzofskyl JA, Belyakov IM.

Curr HIV Res. 2003 Jul;1(3):287-94. Review.

PMID:
15046253
45.
46.

Cytokines in the thymus: production and biological effects.

Yarilin AA, Belyakov IM.

Curr Med Chem. 2004 Feb;11(4):447-64. Review.

PMID:
14965226
47.

Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques.

Edghill-Smith Y, Venzon D, Karpova T, McNally J, Nacsa J, Tsai WP, Tryniszewska E, Moniuszko M, Manischewitz J, King LR, Snodgrass SJ, Parrish J, Markham P, Sowers M, Martin D, Lewis MG, Berzofsky JA, Belyakov IM, Moss B, Tartaglia J, Bray M, Hirsch V, Golding H, Franchini G.

J Infect Dis. 2003 Oct 15;188(8):1181-91. Epub 2003 Oct 10.

PMID:
14551889
48.
49.

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, Snyder JT, Ahlers JD, Franchini G, Moss B, Berzofsky JA.

Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9458-63. Epub 2003 Jul 17.

50.

Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines.

Ahlers JD, Belyakov IM, Berzofsky JA.

Curr Mol Med. 2003 May;3(3):285-301. Review.

PMID:
12699364

Supplemental Content

Loading ...
Support Center